An interventional study of Scorpion Portal Vein Access Kit and Cook Transjugular Liver Access Set in Portal Hypertension, Liver Diseases and Ascites Hepatic, sponsored by Argon Medical Devices. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by Argon Medical Devices · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Hypertension, Portal with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Hypertension, Portal · United States.
Among the 59 studies in Hypertension, Portal with a site in United States, this one is the 41st largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2023, is one of 20 with no phase, and was the 48th registered.
376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.
Browse Hypertension, Portal studies →7 of the 59 studies in Hypertension, Portal with a site in United States are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in United States, Italy
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+ · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–99
Thomas Jefferson University · Sites in United States, Switzerland
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 15 · Phase 3 12 · Phase 4 3
First in 1993; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 60 across 232 interventional studies indexed under Hypertension, Portal.
Median enrollment 30 across the 47 interventional studies, 70 across the 12 observational. Of the 45 that completed or were terminated, 23 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 59 have an industry lead sponsor. The 10 most frequent:
Argon Medical Devices is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Argon Medical Devices has 2 studies filed under Hypertension, Portal — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypertension, Portal with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07046429Weill Medical College of Cornell UniversityAffect of Melatonin on Sleep and Cognition in Cirrhosis | 2026-12-31 |
| NCT06797193Mayo ClinicUltrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Hypertension, Portal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Scorpion or Scorpion X access set
Device: Scorpion Portal Vein Access Kit · Procedure: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Ring or Rosch-Uchida access set
Device: Cook Transjugular Liver Access Set · Procedure: Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Portal Vein Access with Scorpion or Scorpion X set
Portal Vein Access with Ring or Rosch-Uchida set
Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Number of Participants With Procedural Success
Creation of the parenchymal tract between the hepatic vein and an intrahepatic branch of the portal vein confirmed by portogram (CO2/contrast).
Time frame: TIPS Procedure (Day 0), up to 93 minutes
Composite of Major Complications
Major complications associated with the procedure or study device and defined as complications resulting in an unplanned increase in the level of care, prolonged hospitalization, permanent adverse sequelae, or death.
Time frame: Through 30 days post-TIPS procedure
Portal Vein Access (PVA) Time
Time (in minutes) from the first forward motion of the needle to confirmation of portal vein access via portogram.
Time frame: TIPS Procedure (Day 0), up to 52 minutes
Number of Participants With Technical Success
Creation of a shunt (stent bridging) between the portal and systemic veins.
Time frame: TIPS Procedure (Day 0), up to 93 minutes
Number of Needle Passes
Count of needle throws between the hepatic and portal vein to create the parenchymal tract.
Time frame: TIPS Procedure (Day 0), up to 93 minutes
Procedure Duration
Interval (in minutes) from first jugular access for TIPS creation to removal of catheters from the patient.
Time frame: TIPS Procedure (Day 0), up to 93 minutes
Fluoroscopy Time
Measured in minutes
Time frame: TIPS Procedure (Day 0), up to 31.5 minutes
Device-Related Complications
Incidence of complications related to the device as judged by the Investigator
Time frame: Through 30 days post-TIPS procedure
| Milestone | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Started | 2 | 1 |
| Completed | 2 | 1 |
| Not completed | 0 | 0 |
Creation of the parenchymal tract between the hepatic vein and an intrahepatic branch of the portal vein confirmed by portogram (CO2/contrast).
| Participants | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Yes | 2 | 1 |
| No | 0 | 0 |
Major complications associated with the procedure or study device and defined as complications resulting in an unplanned increase in the level of care, prolonged hospitalization, permanent adverse sequelae, or death.
| Events | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Composite of Major Complications | 0 | 1 |
Time (in minutes) from the first forward motion of the needle to confirmation of portal vein access via portogram.
| minutes | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Subject ID 02-001 | — | 52 |
| Subject ID 02-002 | 7 | — |
| Subject ID 02-003 | 8 | — |
Creation of a shunt (stent bridging) between the portal and systemic veins.
| Participants | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Yes | 2 | 1 |
| No | 0 | 0 |
Count of needle throws between the hepatic and portal vein to create the parenchymal tract.
| Number of Needle Passes | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Subject ID 02-001 | — | 3 |
| Subject ID 02-002 | 1 | — |
| Subject ID 02-003 | 1 | — |
Interval (in minutes) from first jugular access for TIPS creation to removal of catheters from the patient.
| Minutes | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Subject ID 02-001 | — | 93 |
| Subject ID 02-002 | 35 | — |
| Subject ID 02-003 | 49 | — |
Measured in minutes
| Minutes | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Subject ID 02-001 | — | 31.5 |
| Subject ID 02-002 | 18.2 | — |
| Subject ID 02-003 | 16.7 | — |
Incidence of complications related to the device as judged by the Investigator
| Number of AEs | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Subject ID 02-001 | — | 2 |
| Subject ID 02-002 | 2 | — |
| Subject ID 02-003 | 4 | — |
Collected over Adverse event reporting started at the time of the TIPS procedure (on Day 0) and ended at Day 30.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TIPS With Scorpion Portal Vein Access Kit | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| TIPS With Cook Transjugular Liver Access Set | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| Hepatic encephalopathyNervous system disorders | 0/2 | 1/1 |
| Abdominal painGastrointestinal disorders | 1/2 | 0/1 |
| Oedema peripheralGeneral disorders | 1/2 | 0/1 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/1 |
| Event | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set |
|---|---|---|
| VomitingGastrointestinal disorders | 0/2 | 1/1 |
| Dyspnea exertionalRespiratory, thoracic and mediastinal disorders | 1/2 | 0/1 |
| Abdominal distensionGastrointestinal disorders | 1/2 | 0/1 |
| Decreased activityGeneral disorders | 1/2 | 0/1 |
| Age, Categorical(Participants) | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 0 | 1 |
| >=65 years | 1 | 1 | 2 |
| Sex: Female, Male(Participants) | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 0 | 1 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | TIPS With Scorpion Portal Vein Access Kit | TIPS With Cook Transjugular Liver Access Set | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 1 | 2 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Oct 2023, 3 months.
Results were first posted in Dec 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Argon Medical Devices